Lose Weight with Belviq.com

Richard Lipman M.D. 7241 SW 63 ave 
Miami, Fl 33143

by Richard Lipman 
7241sw 63 ave
Miami, Fl 33143 USA
305 670-4369
25° 42.190326', -80° 17.746236'

52 week trial of Belviq involving over 3000 obese subjects found an average patient weight loss of 12.7 lbs compared to the placebo group’s results of 4.7 lbs. Average weight losses are difficult to interpret because of the wide ranges of starting weight in these studies. A more productive way to evaluate the effectiveness of weight loss drugs is to study the percent of subjects losing 5% and 10% of their initial body weight. This year long trial showed that 22% of subjects taking Belviq lost 10% or greater bodyweight and 47.5% of Belviq treated patients lost at least 5% of their weight. Belviq® has also been linked to drops in cholesterol levels and other cardiovascular benefits. All in all, Belviq clearly meets the FDA requirements for a medication to be considered an obesity fighting drug which states that at least a third of the trial patients lose at least 5% of their bodyweight over the placebo or that at least two times the patients over the placebo group must have experienced a 5% weight loss. Each of th e graphs below are from
the Bloom Blossom studies. References are on another page.

Side effects reported in clinical testing of Belviq® are very mild and tolerable. The most commonly reported side effect was headaches with approximately 16.8% of Belviq treated subjects experiencing them. Nearly 10.1% of the placebo group experienced headaches. Using the “placebo adjusted” value (treatment value less placebo value) headaches occurred in 6.7% of treated subjects. This was the only side effect that was above a 5% placebo difference. Other side effects with less than 5% occurrence were dry mouth, fatigue, nausea, vomiting, and dizziness. In most people, side effects tended to disappear after a few days.

 Supporting the observations of only very mild side effects is the fact that only 7% of subjects withdrew from the study because of adverse reactions. Another intriguing fact was that the discontinue rates for testing were the same (7%) for actual Belviq® users and the placebo group. This is the lowest placebo adjusted discontinue rate for an obesity drug ever. This is due to the fact that the side effects of Belviq were self limited and so inconsequential. On the other hand, Qsymia studies had much larger dropout rates due to the fact that the side effects were much more common and disturbing to some subjects. lick here to add text.

Side Effects of Belviq Reviewed by Dr Lipman

Dr Lipman Reviews Weight Loss on Belviq

Dr Lipman Reviews Published Studies on Belviq